The influence of chosen adipocytokines on blood pressure values in patients with metabolic syndrome

Kardiologia Polska

Volumn 70, Issue 12, 2012, Pages 1237-1242

  Musialik, Katarzyna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Adipocytokines; Cardiovascular risk; Hypertension

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

EID: 84872083656     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus new worldwide definition. Lancet, 2005; 366: 1059-1062.
2. www.idf.org/metabolic-syndrome, website of the International Diabetes Federation.
3. Biela U, Paja̧k A, Kaczmarczyk-Chałas K et al. Czȩstość wystȩpowania nadwagi i otyłoś ci u kobiet i mȩżczyzn w wieku 20-74 lat. Wyniki programu WOBASZ. Kardiol Pol, 2005; 63 (suppl. 4): 632-635.
4. Steppan M, Bailey T, Bhat S et al. The hormone resistin links obesity to diabetes. Nature, 2001; 409: 307-312.
5. Lozano-Nuevo JJ, Estrada-Garcia T, Vargas-Robles H et al. Correlation between circulating adhesion molecules and resistin levels in hypertensive type-2 diabetic patients. Inflamm Allergy Drug Targets, 2011; 10: 27-31.
6. Reilly P, Lehrke M, Wolfe L et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation, 2005; 111: 932-939.
7. Papadopolous D, Makris T, Krespi P et al. Adiponectin and resistin level in healthy individuals with prehypertension. J Clin Hypertens, 2005; 7: 12: 729-733.
8. Zdrojewski T, Chwojnicki K, Bandosz P. Distribution of C-reactive protein and its relation to arterial hypertension in a country representing a high-risk region for cardiovascular diseases. Blood Press, 2006; 15: 20-26.
9. Bo S, Cavallo-Perin P. Hypertension: shall we focus on adipose tissue? J Am Soc Nephrol, 2010; 21: 1067-1068.
10. Szulińska M, Pupek-Musialik D, Bogdański P. Udział produktów adipocytów w rozwoju insulinooporności u pacjentów z otyłościa̧ i nadciśnieniem tȩtniczym. Nadciśnienie Tȩtnicze, 2004; 8: 33-40.
11. Liu JT, Song E, Xu A et al. Lipocalin-2 deficiency prevents endothalial dysfunction associated with dietary obesity: role of cytochrome P450 2C inhibition. Br J Pharmacol, 2012; 165: 520-531.
12. Adamczak M, Wiecek A, Funahashi T et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens, 2003; 16: 72-75.
13. Mallamaci F, Zoccali C, Cuzzola F et al. Adiponectin in essential hypertension. J Nephrol, 2002; 15: 507-511.
14. Leu HB, Chung CM, Lin SJ et al. Adiponectin gene polymorphism is selectively associated with the concomitant presence of metabolic syndrome and essential hypertension. PLoS One, 2011; 6: 27.
15. Yamauchi T. Kamon J, Waki H et al. The fat- derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 2001; 7: 941-946.
16. Pausova Z, Deslauriers B, Gaudet D et al. Role of tumor necrosis factor-alpha gene locus in obesity and obesity-associated hypertension in French Canadians. Hypertension, 2000; 36: 14-19.
17. Fernandez-Real J, Broch M, Ricart W et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes, 1998; 47: 1757-1762.
18. Cottone S, Vadala A, Vella MC et al. Comparison of tumor necrosis factor and endothelin-1 between essential and renal hypertensive patients. J Hum Hypertens, 1998; 12: 351-354.
19. Linh AS, Torben O., Birgit N. Adiponectin mRNA expression in subcutaneous adipose tissue is reduced in first degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab, 2002; 284: E443-E448.
20. Yamamoto Y, Hirose H, Saito I et al. Correlation of the adi-pocite-derived protein adiponectin resistance index and serum high density lipoprotein cholesterol, independent of body mass index, in the Japanese population. Clin Sci, 2002; 103: 137-142.
21. Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes, 2011; 18: 139-143.
22. Takai S, Jin D, Miyazaki M. Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor gamma. J Pharmacol Sci, 2011; 116: 309-315.
23. Degawa-Yamauchi M, Considine E, Tataranni P. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab, 2003; 88: 5452-5455.
24. Tan M, Chang S, Chang D et al. Association of resistin gene 3′-untranslated region + 629>A polymorhism with type 2 diabetes and hypertension in a Chinese population. J Clin Endocrinol Metabol, 2003; 88: 1258-1263.
25. Zhang MH, Na B, Schiller NB, Whooley MA. Association of resistin with heart failure and mortality in patients with stable coronary heart disease: data from the heart and soul study. J Card Fail, 2011; 17: 24-30.
26. Díez J, Iglesias P, Fernández-Reyes M et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol, 2005; 62: 242-249.